Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Biofactura Announces Entry Into Non-Exclusive License Agreement With Momenta PharmaceuticalsBy: BioFactura BioFactura's Chief Executive Officer and President, Darryl Sampey, said, "This agreement has the potential to benefit patients worldwide. We believe that this commitment by a proven leader in our industry is an endorsement of the value our StableFastTM Biomanufacturing Platform brings. We look forward to continuing to work with Momenta and the expansion of BioFactura's efforts in biosimilars development." BioFactura's Chairman of the Board and Chief Medical Officer, Dr. Jeffrey Hausfeld, said, "BioFactura believes that the establishment of this agreement between BioFactura and Momenta attests to the value of BioFactura's proprietary technology in this space. Our organization is pleased to support the scientific and business development teams at Momenta." About BioFactura BioFactura (Frederick MD) develops and commercializes high-value, highly similar biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high- End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|